Rethinking Idiopathic Pulmonary Fibrosis

Overview

Journal Clin Chest Med

Specialty Pulmonary Medicine

Date 2021 May 24

PMID 34024402

Citations 2

Authors

Justin M Oldham

Carlo Vancheri

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a devastating disease for patients and their loved ones. Since initial efforts to characterize this disease in the 1960s, understanding of IPF has evolved considerably. Such evolution has continually challenged prior diagnostic and treatment paradigms, ushering in an era of higher confidence diagnoses with less invasive procedures and more effective treatments. This review details how research and clinical experience over the past half century have led to a rethinking of IPF. Here, the evolution in understanding of IPF pathogenesis, diagnostic evaluation and treatment approach is discussed.

Citing Articles

A Deep Learning-Based Radiomic Classifier for Usual Interstitial Pneumonia.

Chung J, Chelala L, Pugashetti J, Wang J, Adegunsoye A, Matyga A Chest. 2023; 165(2):371-380.

PMID: 37844797 PMC: 11026174. DOI: 10.1016/j.chest.2023.10.012.

Clinical efficacy and quality of life effect of acetylcysteine plus pirfenidone in patients with pulmonary fibrosis.

Zhang R, Song Z, Guan Y, Zhang J, Zou J, Sun Y Am J Transl Res. 2022; 14(8):5660-5668.

PMID: 36105040 PMC: 9452344.

References

Dutta P, Funston W, Mossop H, Ryan V, Jones R, Forbes R . Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax. 2019; 74(4):346-353. PMC: 6484692. DOI: 10.1136/thoraxjnl-2018-212102. View

Molyneaux P, Willis-Owen S, Cox M, James P, Cowman S, Loebinger M . Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017; 195(12):1640-1650. PMC: 5476909. DOI: 10.1164/rccm.201607-1408OC. View

. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1):646-64. DOI: 10.1164/ajrccm.161.2.ats3-00. View

Richeldi L, Fernandez Perez E, Costabel U, Albera C, Lederer D, Flaherty K . Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2019; 8(1):25-33. DOI: 10.1016/S2213-2600(19)30262-0. View

Grewal J, Morisset J, Fisher J, Churg A, Bilawich A, Ellis J . Role of a Regional Multidisciplinary Conference in the Diagnosis of Interstitial Lung Disease. Ann Am Thorac Soc. 2019; 16(4):455-462. DOI: 10.1513/AnnalsATS.201811-794OC. View

Dempsey T, Sangaralingham L, Yao X, Sanghavi D, Shah N, Limper A . Clinical Effectiveness of Antifibrotic Medications for Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019; 200(2):168-174. DOI: 10.1164/rccm.201902-0456OC. View

Raghu G, van den Blink B, Hamblin M, Brown A, Golden J, Ho L . Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. JAMA. 2018; 319(22):2299-2307. PMC: 6134440. DOI: 10.1001/jama.2018.6129. View

Noble P, Albera C, Bradford W, Costabel U, Glassberg M, Kardatzke D . Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377(9779):1760-9. DOI: 10.1016/S0140-6736(11)60405-4. View

Ghisa M, Marinelli C, Savarino V, Savarino E . Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag. 2019; 15:1081-1093. PMC: 6733342. DOI: 10.2147/TCRM.S184291. View

10.

Putman R, Gudmundsson G, Axelsson G, Hida T, Honda O, Araki T . Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. Am J Respir Crit Care Med. 2019; 200(2):175-183. PMC: 6635786. DOI: 10.1164/rccm.201809-1652OC. View

11.

Huang Y, Ma S, Espindola M, Vij R, Oldham J, Huffnagle G . Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017; 196(2):208-219. PMC: 5519968. DOI: 10.1164/rccm.201607-1525OC. View

12.

De Leon A, Cronkhite J, Yilmaz C, Brewington C, Wang R, Xing C . Subclinical lung disease, macrocytosis, and premature graying in kindreds with telomerase (TERT) mutations. Chest. 2011; 140(3):753-763. PMC: 3168855. DOI: 10.1378/chest.10-2865. View

13.

Troy L, Grainge C, Corte T, Williamson J, Vallely M, Cooper W . Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2019; 8(2):171-181. DOI: 10.1016/S2213-2600(19)30342-X. View

14.

Taskar V, Coultas D . Is idiopathic pulmonary fibrosis an environmental disease?. Proc Am Thorac Soc. 2006; 3(4):293-8. DOI: 10.1513/pats.200512-131TK. View

15.

TOBIN R, Pope 2nd C, Pellegrini C, Emond M, Sillery J, Raghu G . Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998; 158(6):1804-8. DOI: 10.1164/ajrccm.158.6.9804105. View

16.

Parry E, Alder J, Qi X, Chen J, Armanios M . Syndrome complex of bone marrow failure and pulmonary fibrosis predicts germline defects in telomerase. Blood. 2011; 117(21):5607-11. PMC: 3110022. DOI: 10.1182/blood-2010-11-322149. View

17.

Maher T, van der Aar E, Van de Steen O, Allamassey L, Desrivot J, Dupont S . Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial. Lancet Respir Med. 2018; 6(8):627-635. DOI: 10.1016/S2213-2600(18)30181-4. View

18.

Baumgartner K, Samet J, Stidley C, Colby T, Waldron J . Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1997; 155(1):242-8. DOI: 10.1164/ajrccm.155.1.9001319. View

19.

King Jr T, Bradford W, Castro-Bernardini S, Fagan E, Glaspole I, Glassberg M . A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370(22):2083-92. DOI: 10.1056/NEJMoa1402582. View

20.

Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L . Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019; 6(1):e000397. PMC: 6530503. DOI: 10.1136/bmjresp-2018-000397. View